Join our daily newsletter At The Bell to receive exclusive market insights
- Alterity Therapeutics (ATH) doses its first patient in Italy as part of its phase two clinical trial in multiple system atrophy
- The clinical trial is a randomised, placebo-controlled investigation of Alterity’s ATH434 in patients with early stages of the rare and highly debilitating disorder
- The study is expected to include around 60 adults, who will each receive one of two dose levels of the treatment or a placebo
- ATH CEO David Stamler says the company is pleased to have dosed its first participant as it looks to provide a potential new treatment for MSA
- Alterity Therapeutics is up 6.25 per cent, trading at 0.9 cents at 11:55 am AEDT
Alterity Therapeutics (ATH) has dosed its first patient in Italy as part of its phase two clinical trial in multiple system atrophy (MSA).
The clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early stage MSA, a rare and highly debilitating Parkinsonian disorder.
Alterity’s ATH434 is an oral agent which the company said had previously shown “excellent” potential to treat Parkinson’s disease, as well as various Parkinsonian disorders.
The 12-month study will evaluate the effect of ATH434 on neuroimaging and protein biomarkers to determine its efficacy, safety and pharmacokinetics.
The study is expected to include around 60 adults, who will each receive one of two dose levels of ATH434 or a placebo.
“We are pleased to announce that our first participant in Europe has been dosed in our phase 2 clinical trial as we look to bring a potential new treatment option to individuals living with MSA,” Alterity Chief Executive Officer David Stamler said.
“We are grateful to our clinical colleagues in Italy who enrolled quickly following approval of the study”.
Alterity Therapeutics was up 6.25 per cent, trading at 0.9 cents at 11:55 am AEDT.
